ImmunityBio Rises 12% as $9B Valuation Tops Russell 1000 Threshold
IBRX•ImmunityBio’s $9 billion market cap positions it above the $5.7 billion cutoff for the Russell 1000, triggering a 12% stock rally on hopes of index inclusion. Year-to-date U.S. sales of its approved ANKTIVA product and an FDA label-expansion filing for non-muscle invasive bladder cancer have bolstered investor optimism.
1. Russell 1000 Inclusion Prospects
ImmunityBio’s market capitalization of approximately $9 billion exceeds the Russell 1000 cutoff of about $5.7 billion, making it eligible for index inclusion in the semiannual reconstitution based on April 30 data. The updated index takes effect after U.S. market close on June 26, with trading beginning June 29.
2. Stock Rally Driven by Index Hopes
Shares surged 12% on June 26, marking the biggest one-day gain since late March, as investors anticipate passive buying from ETFs and index funds upon possible Russell 1000 entry. Retail sentiment remained bullish, with message volume on social platforms hitting high levels.
3. ANKTIVA Sales and FDA Filing
Year-to-date U.S. sales of the approved ANKTIVA therapy have accelerated, underpinning the stock’s strong performance. The FDA accepted a supplemental application in May to expand ANKTIVA’s label for non-muscle invasive bladder cancer, with a decision expected in January 2027.
